Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968757 | 0.84 | KMO (0.42) | GABRA1CNR2PARP15PARP10PARP2 | |
| SCHEMBL16463484 | 0.77 | POLB (0.41) | GABRA1CNR2JMJD6PARP15PARP10 | |
| SCHEMBL15633149 | 0.74 | GRIN2B (0.44) | JMJD6 | |
| SCHEMBL11661187 | 0.74 | MAPK1 (0.50) | JMJD6PARP15PARP10PARP2 | |
| SCHEMBL11664017 | 0.72 | CYP1A2 (0.58) | CNR2JMJD6 | |
| SCHEMBL28897674 | 0.72 | L3MBTL1 (0.50) | — | |
| SCHEMBL28507405 | 0.71 | CHRM3 (0.47) | — | |
| SCHEMBL15134602 | 0.71 | CNR2 (0.58) | CNR2PARP15PARP10 | |
| SCHEMBL2159773 | 0.71 | CHRNB2 (0.50) | JMJD6PARP15PARP10PARP2 | |
| SCHEMBL2955302 | 0.70 | BCAT2 (0.42) | PARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| CN-103998432-A | Bicyclic compounds | TAKEDA PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | GABRA1 396/4885CNR2 741/4885JMJD6 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.